Coronavirus Update - 24th June 2020

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We remain open for business as usual.

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

Our work and case studies

Challenge: To manufacture drug substance and screen a selection of corresponding pharmaceutically acceptable salt forms.  From the resulting salt forms, choose a candidate which exhibits optimal characteristics for formulation and bioavailability.

Customer:

US Biopharmaceutical

Outcome:

API was manufactured at ARCINOVA and a series of salts subsequently produced.  Each salt form was assessed with respect to salt formation, solubility, hygroscopicity, crystallinity, polymorph tendency, chemical stability and particle size/morphology. An optimal salt form was identified and manufactured at ARCINOVA. 

drug substance Salt Case Study